The predictive value of atherogenic index of plasma in the prediction of cardiovascular events; a fifteen-year cohort study.


Journal

Advances in medical sciences
ISSN: 1898-4002
Titre abrégé: Adv Med Sci
Pays: Netherlands
ID NLM: 101276222

Informations de publication

Date de publication:
Sep 2021
Historique:
received: 11 02 2021
revised: 22 06 2021
accepted: 11 09 2021
pubmed: 26 9 2021
medline: 14 1 2022
entrez: 25 9 2021
Statut: ppublish

Résumé

Cardiovascular events (CVE) are the most prominent cause of death worldwide. Therefore, achieving a precise affordable index for the prediction of healthy cases at increased risk of CVE in early stages and subsequently lessening the rate of CVE mortality is a critical goal of healthcare systems. We aimed to assess the value of Atherogenic index of plasma (AIP) in the prediction of CVE and mortality through a 15-year cohort study. This study was conducted on 6323 over 35-year-old healthy adults from 2001 to 2016. The baseline AIP was measured based on the formula of TG to HDL logarithm and divided into three subgroups of low, intermediate, and high risk of CVD, as <0.11, 0.11-0.21, and ≥0.21, respectively. Eventually, the association of AIP with sociodemographic, lifestyle, traditional CVE-related factors and CVE-induced mortality was evaluated. The multiple cox regression study of AIP values for the prediction of CVE incidence revealed a significant association (OR: 1.57, 95%CI: 1.33-1.85); similar remarkable associations were achieved by controlling age and sex (OR: 1.55, 95%CI: 1.31-1.83), sociodemographic factors (OR: 1.51, 95%CI: 1.29-1.79), sociodemographic plus lifestyle factors (OR: 1.54, 95%CI: 1.30-1.81) and sociodemographic, lifestyle and the traditional CVE-related factors (OR: 1.28, 95%CI: 1.07-1.54). The Kaplan-Meier survival study showed a significant association between AIP levels and CVE-related mortality (p <0.001). In conclusion, AIP is an independent stand-alone factor for the prediction of developing CVE and its-related mortality.

Identifiants

pubmed: 34562749
pii: S1896-1126(21)00049-3
doi: 10.1016/j.advms.2021.09.003
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

418-423

Informations de copyright

Copyright © 2021 Medical University of Bialystok. Published by Elsevier B.V. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of competing interest The authors declare no conflict of interests.

Auteurs

Masoumeh Sadeghi (M)

Cardiac Rehabilitation Research Center, Cardiovascular Research Institute, Isfahan University of Medical Sciences, Isfahan, Iran.

Kiyan Heshmat-Ghahdarijani (K)

Heart Failure Research Center, Cardiovascular Research Institute, Isfahan University of Medical Sciences, Isfahan, Iran. Electronic address: drheshmat@med.mui.ac.ir.

Mohammad Talaei (M)

Institute of Population Health Sciences, Barts and the London School of Medicine, Queen Mary University of London, United Kingdom.

Ali Safaei (A)

Isfahan Cardiovascular Research Center, Cardiovascular Research Institute, Isfahan University of Medical Sciences, Isfahan, Iran.

Nizal Sarrafzadegan (N)

Isfahan Cardiovascular Research Center, Cardiovascular Research Institute, Isfahan University of Medical Sciences, Isfahan, Iran.

Hamidreza Roohafza (H)

Cardiac Rehabilitation Research Center, Cardiovascular Research Institute, Isfahan University of Medical Sciences, Isfahan, Iran.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH